Profile data is unavailable for this security.
About the company
AddLife AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The Company operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The Company operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.
- Revenue in SEK (TTM)10.44bn
- Net income in SEK560.00m
- Incorporated2014
- Employees2.30k
- LocationAddLife ABBrunkebergstorg 5, Box 3145STOCKHOLM 103 62SwedenSWE
- Phone+46 842003830
- Websitehttps://www.add.life/
More ▼
Mergers & acquisitions
| Acquired company | ALIF B:STO since announced | Transaction value |
|---|---|---|
| Opitek International ApS | -22.22% | -- |
| Edge Medical Ltd | 1.45% | 10.33m |
Data delayed at least 15 minutes, as of Feb 10 2026 16:29 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CellaVision AB | 748.45m | 151.41m | 3.78bn | 230.00 | 24.99 | 4.44 | 19.92 | 5.05 | 6.35 | 6.35 | 31.38 | 35.70 | 0.7266 | 2.03 | 6.12 | 3,171,403.00 | 14.70 | 14.59 | 16.81 | 17.10 | 69.11 | 68.05 | 20.23 | 19.64 | 2.43 | 27.89 | 0.031 | 38.49 | 6.78 | 9.39 | 7.99 | 7.25 | 33.00 | -- |
| Medistim ASA | 622.85m | 132.68m | 3.83bn | 154.00 | 28.76 | 9.78 | 24.31 | 6.14 | 7.79 | 7.79 | 36.56 | 22.91 | 1.25 | 0.7679 | 9.67 | 4,341,637.00 | 26.72 | 21.98 | 33.09 | 27.19 | 81.21 | 78.66 | 21.30 | 20.32 | 2.03 | -- | 0.0484 | 85.04 | 6.88 | 9.12 | 0.0087 | 8.11 | 12.53 | 16.89 |
| RaySearch Laboratories AB (publ) | 1.29bn | 219.17m | 5.56bn | 450.00 | 28.25 | 6.73 | 11.49 | 4.31 | 6.39 | 6.39 | 37.69 | 26.82 | 0.6523 | 4.15 | 2.84 | 3,104,637.00 | 11.07 | 2.96 | 16.31 | 4.37 | 92.96 | 90.93 | 16.97 | 5.80 | 1.55 | -- | 0.309 | 67.90 | 16.62 | 9.96 | 149.49 | 32.19 | 0.5132 | -- |
| Revenio Group Oyj | 1.16bn | 196.62m | 5.60bn | 248.00 | 28.51 | 4.82 | 23.14 | 4.84 | 0.6931 | 0.6931 | 4.08 | 4.10 | 0.8087 | 2.91 | 6.94 | 452,352.70 | 13.65 | 14.11 | 15.75 | 17.53 | 71.86 | 70.96 | 16.88 | 20.61 | 1.80 | 10.72 | 0.1036 | 53.12 | 7.19 | 15.91 | -3.20 | 14.64 | 22.93 | 5.92 |
| Xvivo Perfusion AB | 812.17m | 25.16m | 6.10bn | 198.00 | 243.11 | 2.89 | 63.98 | 7.51 | 0.7968 | 0.7968 | 25.76 | 67.10 | 0.34 | 0.8939 | 6.13 | 4,101,844.00 | 1.05 | 3.28 | 1.12 | 3.52 | 73.81 | 73.86 | 3.10 | 10.87 | 3.68 | 1.83 | 0.0557 | 0.00 | -1.25 | 35.19 | -85.39 | -- | -- | -- |
| Arjo AB (publ) | 11.00bn | 334.00m | 6.81bn | 6.94k | 21.84 | 0.9782 | 4.77 | 0.6187 | 1.23 | 1.23 | 40.39 | 27.38 | 0.704 | 4.92 | 6.22 | 1,584,702.00 | 2.14 | 3.26 | 2.91 | 4.80 | 42.59 | 43.42 | 3.04 | 4.78 | 0.8494 | 4.19 | 0.4179 | 48.74 | -2.59 | 3.92 | -32.93 | -8.68 | -- | 2.25 |
| ChemoMetec A/S | 701.60m | 251.87m | 10.08bn | 172.00 | 40.01 | 10.85 | 34.65 | 14.36 | 10.17 | 10.17 | 28.33 | 37.50 | 0.6516 | 0.6662 | 5.54 | 2,679,973.00 | 23.39 | 27.48 | 27.93 | 34.02 | 83.83 | 80.53 | 35.90 | 36.41 | 3.06 | 95.21 | 0.0079 | 48.77 | 21.50 | 18.28 | 36.78 | 25.80 | 19.35 | 36.08 |
| Vitrolife AB | 3.44bn | -5.01bn | 12.10bn | 1.15k | -- | 1.53 | -- | 3.52 | -37.01 | -37.01 | 25.39 | 58.29 | 0.2407 | 3.44 | 5.24 | 2,987,837.00 | -35.09 | -9.46 | -36.79 | -9.86 | 58.24 | 57.81 | -145.74 | -49.19 | 2.73 | 11.33 | 0.169 | -- | -4.68 | 22.53 | -1,077.00 | -- | 68.15 | 6.58 |
| AddLife AB | 10.44bn | 560.00m | 17.41bn | 2.30k | 32.14 | 3.31 | 12.70 | 1.67 | 4.60 | 4.60 | 85.69 | 44.66 | 0.8105 | 3.83 | 5.87 | 4,549,891.00 | 4.36 | 3.82 | 6.05 | 5.80 | 38.09 | 37.80 | 5.38 | 4.66 | 0.6257 | 3.68 | 0.4671 | 31.71 | 1.52 | 14.64 | 122.22 | 1.58 | 22.47 | 0.00 |
| Embla Medical hf | 8.28bn | 743.42m | 18.89bn | 4.19k | 25.21 | 2.36 | 14.68 | 2.28 | 1.22 | 1.22 | 13.62 | 13.05 | 0.5681 | 2.27 | 6.96 | 1,389,003.00 | 5.12 | 4.60 | 6.10 | 5.43 | 62.30 | 62.25 | 9.01 | 7.99 | 0.9445 | 7.22 | 0.3768 | 0.00 | 8.63 | 8.09 | 22.05 | 68.07 | 6.12 | -- |
| Elekta AB (publ) | 17.57bn | 292.00m | 20.33bn | 4.48k | 72.13 | 2.49 | 12.88 | 1.16 | 0.7646 | 0.7646 | 45.97 | 22.11 | 0.5781 | 3.35 | 3.09 | 3,872,796.00 | 0.9511 | 3.48 | 1.70 | 6.21 | 38.17 | 38.22 | 1.65 | 6.02 | 0.7918 | 7.51 | 0.4724 | 92.20 | -0.5685 | 4.29 | -81.80 | -26.22 | 15.56 | 5.92 |
| Ambu A/S | 8.66bn | 774.00m | 28.87bn | 5.43k | 42.24 | 3.81 | 21.98 | 3.33 | 2.04 | 2.04 | 22.85 | 22.64 | 0.8135 | 1.95 | 7.18 | 1,130,201.00 | 7.27 | 4.06 | 8.49 | 4.82 | 60.07 | 59.33 | 8.94 | 5.48 | 1.67 | 20.74 | 0.0845 | 21.23 | 11.98 | 11.10 | 159.15 | 20.37 | -2.24 | 7.17 |
| Asker Healthcare Group AB | 16.41bn | 469.00m | 30.64bn | 4.51k | 41.76 | -- | 24.95 | 1.87 | 1.92 | 1.92 | 54.47 | -- | 1.15 | 5.10 | 9.34 | 5,010,379.00 | 3.37 | -- | 4.36 | -- | 40.43 | -- | 2.94 | -- | 0.9924 | 3.40 | 0.4561 | -- | 11.69 | -- | 77.34 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to AddLife AB's reporting currency: Swedish Krona SEK
50.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AMF Fonder ABas of 31 Dec 2024 | 10.70m | 9.08% |
| SEB Funds ABas of 31 Dec 2025 | 9.50m | 8.06% |
| ODIN Forvaltning ASas of 30 May 2025 | 7.90m | 6.70% |
| Cliens Kapitalf�rvaltning ABas of 31 Dec 2024 | 6.63m | 5.63% |
| F�rsta AP-fondenas of 31 Dec 2024 | 6.10m | 5.18% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 4.31m | 3.66% |
| Swedbank Robur Fonder ABas of 30 Dec 2025 | 4.26m | 3.62% |
| Fidelity Management & Research Co. LLCas of 30 Dec 2025 | 3.57m | 3.03% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 3.48m | 2.95% |
| Tredje AP-fondenas of 31 Dec 2024 | 3.33m | 2.82% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
